Please login to the form below

Not currently logged in

Endo to collaborate with India-based CRO GVK Biosciences

Will develop small molecule against undisclosed target in pain

GVK BiosciencesEndo has entered a deal with the India-based contract research organisation (CRO) GVK Biosciences to develop small molecules targeting an unnamed protein.

As part of the deal, financial details of which remain undisclosed, GVK Biosciences will deliver a clinical candidate for Endo to then develop and commercialise.

The collaboration is the first to come from what GVK Biosciences calls its Early Discovery Assets (EDA) programme, which is seeing the company develop a portfolio of discovery project assets for potential early stage partnering.

A specific indication for the Endo collaboration was not given, although the EDA portfolio is focused around pain and inflammation, which is in line with Endo's specialities of pain, urology/oncology and endocrinology.

According to GVK, the EDA programme involves the CRO developing these assets to a stage where they can demonstrate value as a treatment, before looking for partnership opportunities to continue development.

Manni Kantipudi, CEO of GVK Biosciences, said: “We are delighted to partner with Endo as it continues to build its discovery pipeline through external collaborations.

“This collaboration also confirms the value of our differentiated EDA concept, conceived to collaborate with pharmaceutical partners on discovery projects, from target to clinical candidates.”

The collaboration with Endo comes in the same month that GVK Biosciences entered a deal with another US-based pharma company.

In early January, it agreed to partner with Onconova Therapuetics to develop two of Onconova's discovery targets in cancer using GVK's discovery platform.

The CRO also has an arrangement with Astellas Pharma to provide the Japan-based pharma company with access to its 'structure activity relationship' (SAR) database, which includes data for more than 5.1 million compounds.

29th January 2013

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

Specialising in medical device market research, our approach is people-centric and we thrive on making connections with clients and research...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...